NCT00886782 - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 4, 2010

Study Completion Date

August 4, 2010

Conditions

Advanced Solid CancersMetastatic Cancer

Interventions

DRUG

Cdc7-inhibitor

Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months

Trial Locations (6)

Karmanos Cancer Institute, Detroit

Local Institution, Villejuif

Dana-Farber Cancer Institute-Vendor, Boston

Dana-Farber Cancer Institute, Boston

Local Institution - 003, Toronto

Local Institution, Toronto